[
  {
    "ts": null,
    "headline": "Are You Looking for a High-Growth Dividend Stock?",
    "summary": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.",
    "url": "https://finnhub.io/api/news?id=86bacde7a20876424662bbc7881477c7bd78075a3d9e5cb95930856d07f885e9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772037905,
      "headline": "Are You Looking for a High-Growth Dividend Stock?",
      "id": 139223921,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.",
      "url": "https://finnhub.io/api/news?id=86bacde7a20876424662bbc7881477c7bd78075a3d9e5cb95930856d07f885e9"
    }
  },
  {
    "ts": null,
    "headline": "Can J&J Sustain Its Double-Digit Oncology Growth Streak?",
    "summary": "JNJ's oncology sales surged in 2025 as Darzalex and new drugs powered growth. With a $50B target by 2030, can its cancer momentum last?",
    "url": "https://finnhub.io/api/news?id=ba45cee31689e9da54a64d074b4fc30860d13dcf0660dec8cbfde6c06856b970",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772027340,
      "headline": "Can J&J Sustain Its Double-Digit Oncology Growth Streak?",
      "id": 139210551,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "JNJ's oncology sales surged in 2025 as Darzalex and new drugs powered growth. With a $50B target by 2030, can its cancer momentum last?",
      "url": "https://finnhub.io/api/news?id=ba45cee31689e9da54a64d074b4fc30860d13dcf0660dec8cbfde6c06856b970"
    }
  },
  {
    "ts": null,
    "headline": "Quantum Surgical buys J&J’s NeuWave",
    "summary": "Quantum, developer of the Epione robotic platform for cancer treatment, said the acquisition supports its strategy of reducing cancer mortality through robot-assisted tumor ablation.",
    "url": "https://finnhub.io/api/news?id=3bdffc5a7ccbcba45c6077c62ee2455e067dc86d6e5a169780688b383ee39067",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772018431,
      "headline": "Quantum Surgical buys J&J’s NeuWave",
      "id": 139215448,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Quantum, developer of the Epione robotic platform for cancer treatment, said the acquisition supports its strategy of reducing cancer mortality through robot-assisted tumor ablation.",
      "url": "https://finnhub.io/api/news?id=3bdffc5a7ccbcba45c6077c62ee2455e067dc86d6e5a169780688b383ee39067"
    }
  },
  {
    "ts": null,
    "headline": "How Shifting Analyst Targets Are Rewriting The Johnson & Johnson (JNJ) Investment Story",
    "summary": "Johnson & Johnson’s fair value estimate has been adjusted from US$231.25 to US$232.50, a move of about 0.5% that fine tunes the price target rather than overhauls it. This shift comes as recent Street research has leaned more positive, with several firms lifting targets and one upgrade, even as others argue that a lot of potential upside may already be reflected. As you read on, you will see how these changing targets fit into the broader analyst narrative and how you can track it as it...",
    "url": "https://finnhub.io/api/news?id=0686aa0f0b3280f30ce3c1110f05f33361e8a517bebc75dd19b15b10771c8bca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772014465,
      "headline": "How Shifting Analyst Targets Are Rewriting The Johnson & Johnson (JNJ) Investment Story",
      "id": 139206461,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson’s fair value estimate has been adjusted from US$231.25 to US$232.50, a move of about 0.5% that fine tunes the price target rather than overhauls it. This shift comes as recent Street research has leaned more positive, with several firms lifting targets and one upgrade, even as others argue that a lot of potential upside may already be reflected. As you read on, you will see how these changing targets fit into the broader analyst narrative and how you can track it as it...",
      "url": "https://finnhub.io/api/news?id=0686aa0f0b3280f30ce3c1110f05f33361e8a517bebc75dd19b15b10771c8bca"
    }
  },
  {
    "ts": null,
    "headline": "Oruka Therapeutics: A Potential Future Psoriasis Play",
    "summary": "Oruka Therapeutics: A Potential Future Psoriasis Play",
    "url": "https://finnhub.io/api/news?id=20fd663d56461d661f04230d74318f359bae608478fd3016a1ee3b0648a05e09",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772013790,
      "headline": "Oruka Therapeutics: A Potential Future Psoriasis Play",
      "id": 139209740,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=20fd663d56461d661f04230d74318f359bae608478fd3016a1ee3b0648a05e09"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Enterprise Technology Analysis Report 2025: Accelerators, Digital Strategies, Innovation Programs, Incubators, Technology Initiatives, Partnerships, Investment & Acquisition",
    "summary": "Johnson & Johnson's market opportunities lie in its innovative medicines across key therapy areas and advanced medical devices. Its focus on digital transformation, tech partnerships, and strategic innovations highlights potential in global healthcare technology advancements.Dublin, Feb. 25, 2026 (GLOBE NEWSWIRE) -- The \"Enterprise Tech Ecosystem Series: Johnson & Johnson 2025\" has been added to ResearchAndMarkets.com's offering. A deep dive into J&J's technological endeavors, highlighting digit",
    "url": "https://finnhub.io/api/news?id=5e75fc1ec0915c098fe8d87ffc346ef4723eaa5ad75fe9a90ff2f168864c4823",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772010480,
      "headline": "Johnson & Johnson Enterprise Technology Analysis Report 2025: Accelerators, Digital Strategies, Innovation Programs, Incubators, Technology Initiatives, Partnerships, Investment & Acquisition",
      "id": 139205923,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson's market opportunities lie in its innovative medicines across key therapy areas and advanced medical devices. Its focus on digital transformation, tech partnerships, and strategic innovations highlights potential in global healthcare technology advancements.Dublin, Feb. 25, 2026 (GLOBE NEWSWIRE) -- The \"Enterprise Tech Ecosystem Series: Johnson & Johnson 2025\" has been added to ResearchAndMarkets.com's offering. A deep dive into J&J's technological endeavors, highlighting digit",
      "url": "https://finnhub.io/api/news?id=5e75fc1ec0915c098fe8d87ffc346ef4723eaa5ad75fe9a90ff2f168864c4823"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson: Strong Run May Be Ending (Rating Downgrade)",
    "summary": "Johnson & Johnson: Strong Run May Be Ending (Rating Downgrade)",
    "url": "https://finnhub.io/api/news?id=8480ef9b41c59286c2fb79739b124a21b27386b053413babc85e698721edfac1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772004636,
      "headline": "Johnson & Johnson: Strong Run May Be Ending (Rating Downgrade)",
      "id": 139206843,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=8480ef9b41c59286c2fb79739b124a21b27386b053413babc85e698721edfac1"
    }
  }
]